In these studies, experimental results from FOXM1 knockout mice and in vitro studies in which FOXM1 was inhibited by a using pharmacologic agent (i.e., thiostrepton) or gene knockdown support the concept that FOXM1 contributes to the oncogenicity of these cancers. The gene discussed is FOXM1; the disease is cancer.